TIDMIVO
16 April 2009
Imperial Innovations Group
("Imperial Innovations")
Notice of Half Year Results
Imperial Innovations (AIM: IVO), a leading technology commercialisation and
investment company, will announce its half year results, for the six months
ended 31 January 2009, on 27 April 2009.
For further information please contact:
Imperial Innovations
Susan Searle, Chief Executive
Diana Crisp, PR Manager
Tel. +44 (0)20 7594 6589
M:Communications
Patrick d'Ancona or Ben Simons
Tel. +44 (0)20 7153 1540
JPMorgan Cazenove (NOMAD to Imperial Innovations)
Steve Baldwin
Tel. +44(0)20 7588 2828
About Imperial Innovations
Imperial Innovations is one of the UK's leading technology commercialisation
and investment companies. Founded in 1986 and admitted to the AIM Market of the
London Stock Exchange in 2006, Imperial Innovations' access to early stage
technology and intellectual property is unparalleled. Imperial Innovations'
integrated commercialisation approach encompasses the identification of ideas,
the protection of intellectual property, the development and licensing of
technology and the formation, incubation and funding, through investment, of
technology businesses.
Based at Imperial College, London, Imperial Innovations' portfolio of equity
holdings in more than 80 companies spans across its four core areas of
Healthcare, Engineering, Energy & Environment and Software & IT.
Companies in the portfolio include: Nexeon (lithium ion battery technology),
Circassia (allergy therapeutics), Polytherics (drug development), Evo Electric
(electric motor and generator solutions), Respivert (respiratory drug
development), Quantasol (solar concentrators) and Inforsense (business
analytics)
Imperial Innovations has already realised significant value from its
investments to date including from a recent trade sale in December 2008 when
Thiakis Limited, a company in which Imperial Innovations had a 23.7% stake, was
sold for up to GBP100 million to US-based Wyeth Pharmaceuticals.
www.imperialinnovations.co.uk
END
|